Paper Details

  1. Home
  2. Paper Details

A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment. 2. Second report: the results from 12 to 24 months.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of tuberculosis patients compared three different continuation regimens after 3 months of standard treatment. All three regimens (PAS plus isoniazid daily, streptomycin plus isoniazid twice weekly, and a combination of the two) were highly effective after 2 years. Continuing treatment beyond 18 months did not improve outcomes. The study also found that extending sanatorium treatment from 3 to 6 months did not provide any benefit. The study concludes that all three continuation regimens are equally effective, but the intermittent regimens allow for closer monitoring of treatment adherence.
Paper Details　
Original Abstract of the Article :
Further results of a controlled clinical trial of tuberculosis chemotherapeutic regimens, carried out with the cooperation of all 7 tuberculosis hospitals and 27 of the 30 chest clinics of the Central Bohemian region and 6 of the 10 chest clinics of Prague, are presented. Following 3 months of stand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480999/

データ提供：米国国立医学図書館（NLM）

Finding the Sweet Spot for Tuberculosis Chemotherapy

Tuberculosis (TB), a contagious bacterial infection, remains a significant public health challenge. This study delves into the effectiveness of various chemotherapy regimens for TB treatment, aiming to determine the optimal duration and frequency of treatment. The researchers conducted a controlled clinical trial to compare the efficacy of different continuation regimens following an initial three-month standard triple chemotherapy.

A Comparative Study Reveals Optimal Treatment Regimens

The study found that all three continuation regimens were equally effective in treating TB. However, the intermittent regimens, involving twice-weekly or once-weekly administration, offered greater patient convenience and control over treatment adherence. Importantly, the study also found that extending chemotherapy beyond 18 months provided no additional benefit.

Simplifying Treatment for Better Outcomes

These findings provide valuable information for healthcare providers treating TB. The study highlights the importance of finding the right balance between effective treatment and patient convenience, suggesting that intermittent regimens might be a more suitable approach.

Dr.Camel's Conclusion

In the ongoing battle against TB, researchers are constantly seeking ways to optimize treatment strategies. This study provides valuable insights into the effectiveness of different chemotherapy regimens, suggesting that intermittent treatment might be a viable alternative, much like a camel taking strategic breaks during a long desert journey.

Date :
  1. Date Completed 1973-09-26
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

4578361

DOI: Digital Object Identifier

PMC2480999

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.